These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29047144)

  • 1. MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients.
    Trifa AP; Bănescu C; Bojan AS; Voina CM; Popa Ș; Vișan S; Ciubean AD; Tripon F; Dima D; Popov VM; Vesa ȘC; Andreescu M; Török-Vistai T; Mihăilă RG; Berbec N; Macarie I; Coliţă A; Iordache M; Cătană AC; Farcaș MF; Tomuleasa C; Vasile K; Truică C; Todincă A; Pop-Muntean L; Manolache R; Bumbea H; Vlădăreanu AM; Gaman M; Ciufu CM; Popp RA
    Am J Hematol; 2018 Jan; 93(1):100-106. PubMed ID: 29047144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
    Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline variations at
    Chiang YH; Chang YC; Lin HC; Huang L; Cheng CC; Wang WT; Cheng HI; Su NW; Chen CG; Lin J; Chang YF; Chang MC; Hsieh RK; Chou WC; Lim KH; Kuo YY
    Oncotarget; 2017 Sep; 8(44):76204-76213. PubMed ID: 29100304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.
    Tapper W; Jones AV; Kralovics R; Harutyunyan AS; Zoi K; Leung W; Godfrey AL; Guglielmelli P; Callaway A; Ward D; Aranaz P; White HE; Waghorn K; Lin F; Chase A; Baxter EJ; Maclean C; Nangalia J; Chen E; Evans P; Short M; Jack A; Wallis L; Oscier D; Duncombe AS; Schuh A; Mead AJ; Griffiths M; Ewing J; Gale RE; Schnittger S; Haferlach T; Stegelmann F; Döhner K; Grallert H; Strauch K; Tanaka T; Bandinelli S; Giannopoulos A; Pieri L; Mannarelli C; Gisslinger H; Barosi G; Cazzola M; Reiter A; Harrison C; Campbell P; Green AR; Vannucchi A; Cross NC
    Nat Commun; 2015 Apr; 6():6691. PubMed ID: 25849990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients.
    Matsuguma M; Yujiri T; Yamamoto K; Kajimura Y; Tokunaga Y; Tanaka M; Tanaka Y; Nakamura Y; Tanizawa Y
    Int J Hematol; 2019 Dec; 110(6):690-698. PubMed ID: 31571131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.
    Ohyashiki JH; Yoneta M; Hisatomi H; Iwabuchi T; Umezu T; Ohyashiki K
    BMC Med Genet; 2012 Jan; 13():6. PubMed ID: 22251709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
    Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Ferreira Cristina S; Polo B; Lacerda JF
    Semin Hematol; 2018 Oct; 55(4):215-222. PubMed ID: 30502850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
    He ZP; Tian HY; Tan M; Wu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):842-848. PubMed ID: 29950230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients.
    Zhang X; Hu T; Wu Z; Kang Z; Liu W; Guan M
    Int J Hematol; 2012 Nov; 96(5):611-6. PubMed ID: 23054641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
    Ha JS; Kim YK
    Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.
    Zhang SJ; Qiu HX; Li JY; Shi JY; Xu W
    Int J Lab Hematol; 2010 Aug; 32(4):381-6. PubMed ID: 20331763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
    Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE
    Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
    Singdong R; Siriboonpiputtana T; Chareonsirisuthigul T; Kongruang A; Limsuwanachot N; Sirirat T; Chuncharunee S; Rerkamnuaychoke B
    Asian Pac J Cancer Prev; 2016 Oct; 17(10):4647-4653. PubMed ID: 27892678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.
    Hinds DA; Barnholt KE; Mesa RA; Kiefer AK; Do CB; Eriksson N; Mountain JL; Francke U; Tung JY; Nguyen HM; Zhang H; Gojenola L; Zehnder JL; Gotlib J
    Blood; 2016 Aug; 128(8):1121-8. PubMed ID: 27365426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients.
    Tanaka M; Yujiri T; Ito S; Okayama N; Takahashi T; Shinohara K; Azuno Y; Nawata R; Hinoda Y; Tanizawa Y
    Int J Hematol; 2013 Mar; 97(3):409-13. PubMed ID: 23430670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms.
    Cavalloni C; Rumi E; Ferretti VV; Pietra D; Roncoroni E; Bellini M; Ciboddo M; Casetti IC; Landini B; Fugazza E; Troletti D; Astori C; Cazzola M
    Oncotarget; 2017 May; 8(20):33416-33421. PubMed ID: 28422716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
    Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
    Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
    Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
    Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.